Clinical Trials Logo

Clinical Trial Summary

We have in a pilot study found that serum calcium levels change in response to hCG stimulation test. We observed that serum calcium level measured at baseline and 72 hours after hCG stimulation were different in men with gonadal insufficiency referred for this stimulation test. Now we want to investigate a large cohort of men referred for hCG stimulation test due to suspected impaired gonadal function.


Clinical Trial Description

Introduction:

hCG signals through the LHCGR receptor and is know to stimulate testosterone production. hCG stimulation tests are therefore used to evaulate the capacity of the testis to respond to LH/hCG and thereby determine the degree og gonadal insufficiency and need for testosterone supplementation. Some groups have found LHCRG in extragondal tissues indicating a direct effect of hCG/LH outside the gonads. We noticed that some men with gonadal insuffciency had a low calcium level after hCG stimulation test. Now we would like to investigate whether this putative effect on calcium homeostasis of hCG is due to a direct effect or an indirect effect through testosterone or other sex steroids that also change in response to hCG stimulation. Moreover, we would like to clarify whether the chnage in calcium is compensated by classical regulators such as PTH, 1,25OH2D3, calcitonin, phosphate, CTX, alkaline phosphatase or other factors.

Aim of study:

The purpose of this study is to describe changes in calcium and calciotropic hormones after hCG stimulation test

DESIGN This is a prospective observational study

Patients and methods 100 men referred for hCG stimulation test due to suspected gonadal insuffciency age 18-60 years at Department of growth and reproduction, Rigshospitalet

Exclusion criteria are

intake of high dose calcium (above 1 mg daily) Known Disorders related to calcium metabolism, hypercalcemia, Granulomatous disease such as Wegener, tuberculosis, etc,

SAMPLE SIZE CALCULATION AND STATISTICS By using a test level of 5% (level of significance), power of 80% and at least 100 men completing the trial will enable us to detect a change in calcium of 10%, and a change in serum PTH of 30%.

SCREENING AND TIME COURSE Men referred for hCG stimulation test at ourDepartment will be screened for eligibility to the study. Those who meet the criteria for participation will be informed, and if they consent allocated to the study.

Each person will have one blood sampling performed prior to the test and 72 and 96 hours after the test.

Blood samples Venus blood is drawn preoperatively before hCG administration, 72 and 96 hours after. Serum will be send for analysis within 45 minutes and the rest frozen within 1 hour and will be stored at minus 20 degrees celsius until analysis.

OUTCOME MEASUREMENTS

Primary endpoints

•Changes in total, albumin corrected and ionized calcium

Main Secondary endpoints

- Changes in PTH

- Changes in 1,25OH2D3

- Changes in Phosphate

- Changes in FGF23

- Changes in Calcitonin

- Changes in LHCGR in serum

- Changes in Cortisol

- Changes in total and free testosterone

- Changes in total and free estradiol

- Changes in kidney function (GFR/creatinin)

- Changes in gonadotropins

- Changes in 25OHD, 24,25OH2D3

- Changes in serum concentrations of putative regulators and downstream signals osteocalcin, osteopontin, RANKL, osteoprotegerin (OPG), alpha Klotho, Sclerostin and IGF-1.

Temporal changes in serum level of binding proteins. differences for vitamin D binding protein, albumin and sex hormone binding globulin.

Predefined subgroups orchiectomized men/ bilaterally irradiated testis High versus low baseline estradiol/testosterone Low/high calcium/PTH baseline

ANALYSIS AND INTERVENTION

Reproductive hormones and growth factors will be analysed at dept. of GR, Rigshospitalet. Other serum analyses will be analysed at Department of clinical biochemistry, and Aarhus Kommune Hospital

ETHICS AND SIDE EFFECTS All the patients will have full-filled their investigation, before they are invited to the study. They will be informed of potential adverse effects, and they can leave the trial at any point without any consequences. This study poses no additional risk to the patients except for the blood samples as everything else is according to standard clinical practice.

PUBLICATION OF RESULTS All results, positive or negative will be submitted to peer reviewed scientific journals. Data will successively be obtained and transferred to a statistical database. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03254641
Study type Observational
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase
Start date April 1, 2017
Completion date October 6, 2020

See also
  Status Clinical Trial Phase
Completed NCT04467697 - Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men Phase 3
Active, not recruiting NCT04326673 - Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
Completed NCT03203681 - Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Phase 4
Completed NCT01904734 - Clomid in Men With Low Testosterone With and Without Prior Treatment Phase 2
Completed NCT00400335 - Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride Phase 1
Completed NCT00398580 - 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men Phase 2
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT03282682 - Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male N/A
Terminated NCT03335254 - A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Phase 1/Phase 2
Terminated NCT05205837 - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial Phase 4
Completed NCT03747003 - Gonadal Function in Young to Middle Aged HIV-infected Men
Withdrawn NCT03176537 - Periodontal Profile of Hypogonadic Men Phase 4
Recruiting NCT04049331 - Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Phase 2
Completed NCT03541395 - Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males N/A
Recruiting NCT05249634 - Testosterone Treatment in Men With Chronic Kidney Disease Phase 2
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Not yet recruiting NCT04717362 - The Effects of Natesto For Treatment Of Hypogonadism Early Phase 1
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Completed NCT04456296 - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Phase 4
Not yet recruiting NCT06312761 - Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 Phase 1/Phase 2